In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fiber/statin combination

This article was originally published in The Tan Sheet

Executive Summary

Taking 10 mg simvastatin with 15 g of Procter & Gamble's Metamucil daily can reduce cholesterol as effectively as a 20 mg dose of the statin alone, Abel Moreyra, MD, Robert Wood Johnson Medical School, et al., report at the American Heart Association's annual meeting in New Orleans Nov. 9. The eight-week study enrolled 67 subjects with CHD risk factors in three trial arms. Participants were randomized to simvastatin 20 mg plus placebo (Tang), simvastatin 10 mg plus placebo or simvastatin 10 mg plus 15 g psyllium (Metamucil); the fiber was taken three times daily with meals. The results suggest a treatment option that may carry reduced side effects, the researchers point out...

You may also be interested in...

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.

QUOTED. 25 February 2020. David Maman.

Israel-based hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what's co-founder and CEO, David Maman, said about the technology here.   

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts